Cover Image
市場調查報告書

牙周病:開發中產品分析

Periodontitis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 276008
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
牙周病:開發中產品分析 Periodontitis - Pipeline Review, H1 2017
出版日期: 2017年03月22日 內容資訊: 英文 48 Pages
簡介

牙周病是造成軟組織受損的牙齦感染,會破壞支撐牙齒的骨頭。常見的症狀有牙齦腫、牙齦呈鮮紅色/淡紫色、口臭、齒間呈現鮮紅色/淡紫色等。危險因子有牙齦炎、遺傳、糖尿病、年齡、藥物濫用、免疫力低落等。

本報告提供牙周病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息新聞稿等資訊。

簡介

  • 調查範圍

牙周病概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

牙周病:企業開發中的治療藥

牙周病:大學/機關研究中的治療藥

牙周病:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

牙周病:企業開發中的產品

牙周病:大學/機關研究中的產品

牙周病的治療藥的開發企業

  • Amyndas Pharmaceuticals LLC
  • C3 Jian, Inc
  • CSL Limited
  • Ensol Biosciences Inc.
  • Enzo Biochem, Inc.
  • Geistlich Pharma AG
  • 科研製藥
  • TGV-Laboratories

牙周病:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

牙周病:暫停中的計劃

牙周病:開發中止的產品

牙周病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9092IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Periodontitis - Pipeline Review, H1 2017, provides an overview of the Periodontitis (Mouth And Dental Disorders) pipeline landscape.

Periodontitis is a gum infection that damages the soft tissue and destroys the bone that supports teeth. Signs and symptoms of periodontitis include swollen gums, bright red or purplish gums, bad breath, bright red or purplish gums and spaces developing between teeth. Risk factors include gingivitis, heredity, diabetes, age, substance abuse and weakened immune system.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Periodontitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Periodontitis (Mouth And Dental Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Periodontitis (Mouth And Dental Disorders) pipeline guide also reviews of key players involved in therapeutic development for Periodontitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Periodontitis (Mouth And Dental Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Periodontitis (Mouth And Dental Disorders).
  • The pipeline guide reviews pipeline therapeutics for Periodontitis (Mouth And Dental Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Periodontitis (Mouth And Dental Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Periodontitis (Mouth And Dental Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Periodontitis (Mouth And Dental Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Periodontitis (Mouth And Dental Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Periodontitis (Mouth And Dental Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Periodontitis - Overview
  • Periodontitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Periodontitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Periodontitis - Companies Involved in Therapeutics Development
    • Amyndas Pharmaceuticals LLC
    • C3J Therapeutics Inc
    • CSL Ltd
    • Ensol Biosciences Inc
    • Geistlich Pharma AG
    • Kaken Pharmaceutical Co Ltd
  • Periodontitis - Drug Profiles
    • AMY-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Antagonize C5aR for Periodontitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GM-0111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Hesed-3000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PODCRC-OHS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-10001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Activate Del-1 for Multiple Sclerosis and Periodontitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Periodontitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-266 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Periodontitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • taurolidine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trafermin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Periodontitis - Dormant Projects
  • Periodontitis - Discontinued Products
  • Periodontitis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 15, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 to Treat Patients with Periodontitis
      • Mar 07, 2016: Penn Team Reverses Signs of Naturally Occurring Chronic Periodontitis
      • Oct 01, 2015: Kaken Submits a New Drug Application for "KCB-1D", Medicinal Product for Periodontal Regeneration
      • May 20, 2014: Penn Team Identifies Promising New Target for Gum Disease Treatment
      • Mar 30, 2012: Kaken Pharma To Initiate Additional Phase III Trial For KCB-1D
      • Oct 21, 2004: Kaken Pharmaceutical Announces Results Of Early Phase II Clinical Trial On KCB-1D
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Periodontitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Periodontitis - Pipeline by Amyndas Pharmaceuticals LLC, H1 2017
  • Periodontitis - Pipeline by C3J Therapeutics Inc, H1 2017
  • Periodontitis - Pipeline by CSL Ltd, H1 2017
  • Periodontitis - Pipeline by Ensol Biosciences Inc, H1 2017
  • Periodontitis - Pipeline by Geistlich Pharma AG, H1 2017
  • Periodontitis - Pipeline by Kaken Pharmaceutical Co Ltd, H1 2017
  • Periodontitis - Dormant Projects, H1 2017
  • Periodontitis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Periodontitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top